Last $4.02 USD
Change Today +0.07 / 1.77%
Volume 61.7K
ADMP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

adamis pharmaceuticals corp (ADMP) Snapshot

Open
$3.93
Previous Close
$3.95
Day High
$4.07
Day Low
$3.87
52 Week High
12/5/13 - $11.90
52 Week Low
08/15/14 - $2.62
Market Cap
42.2M
Average Volume 10 Days
118.3K
EPS TTM
$-1.36
Shares Outstanding
10.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADAMIS PHARMACEUTICALS CORP (ADMP)

Related News

No related news articles were found.

adamis pharmaceuticals corp (ADMP) Related Businessweek News

No Related Businessweek News Found

adamis pharmaceuticals corp (ADMP) Details

Adamis Pharmaceuticals Corporation, a biopharmaceutical company, is engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergies, oncology, and immunology. Its specialty pharmaceutical division has four products in its pipeline, including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease (COPD); and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. The company’s biotechnology division focuses on the development of therapeutic vaccine product candidates and cancer drugs for patients with unmet medical needs in the global cancer markets. Its four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer; and three drugs comprise APC-100, APC-200, and APC-300 for the treatment of prostate cancer. The company is headquartered in San Diego, California.

adamis pharmaceuticals corp (ADMP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $625.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $247.7K
Vice President of Operations
Total Annual Compensation: $225.0K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $287.7K
Compensation as of Fiscal Year 2014.

adamis pharmaceuticals corp (ADMP) Key Developments

Adamis Pharmaceuticals Corporation Announces Board Changes

Adamis Pharmaceuticals Corporation announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board. Mr. Rothermel currently serves as a board member and chairman of the audit committee of Medcor and has also served as a board member of Cerescan. William C. Denby: From 2002-2014, Mr. Denby was Senior Vice President, Commercial Operations at Santarus Inc. which was acquired by Salix in January of 2014. These three new independent board members have replaced Tina S. Nova, Ph.D., Craig A. Johnson and Kenneth M. Cohen, who resigned from the Board.

FDA Accepts Adamis Pharmaceuticals's New Drug Application for Epinephrine Injection

Adamis Pharmaceuticals Corp. announced that its New Drug Application for EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) for the emergency treatment of allergic reactions (Type I) including anaphylaxis has been accepted for review by the FDA. The regulatory decision for marketing authorization for the PFS in the U.S. is expected in the first half of 2015. If approved, Epinephrine Pre-Filled Syringe will be the company's first product to generate revenues.

Adamis Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt

Adamis Pharmaceuticals Corporation filed its 10-K on Jun 23, 2014 for the period ending Mar 31, 2014. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMP:US $4.02 USD +0.07

ADMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Delcath Systems Inc $2.40 USD +0.03
View Industry Companies
 

Industry Analysis

ADMP

Industry Average

Valuation ADMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADAMIS PHARMACEUTICALS CORP, please visit www.adamispharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.